140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial

J-P Ayoub,M.L Friedlander,V.C Dieras,H Wildiers,B Arun,H.S Han,S Puhalla,Y Shparyk,E.H Jakobsen,M.G Kundu,M Wu,C Ratajczak,D Maag,B Kaufman

doi:10.1016/j.annonc.2020.03.241

140O Veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: Results in hormone receptor-positive and triple-negative breast cancer subgroups from the phase III BROCADE3 trial

J-P Ayoub, M.L Friedlander + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2020.03.241

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: May 1, 2020
Citations: 5	License type: publisher-specific-oa

Affiliation: Centre Hospitalier de l’Université de Montréal, Prince of Wales Hospital, KU Leuven, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, AbbVie (United States), Tel Aviv University

#Triple-negative Breast Cancer Subgroups #Carboplatin-paclitaxel In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In BROCADE3 (NCT02163694), addition of the PARP1/2 inhibitor veliparib (Vel) to carboplatin-paclitaxel (C-P) significantly prolonged progression-free survival (PFS) in patients (pts) with HER2-negative locally advanced/metastatic gBRCA-associated breast cancer (BC; hazard ratio=0.71 [95% CI 0.57, 0.88], P=.002). Here we report efficacy and safety in hormone receptor-positive (HR+) and triple-negative BC (TNBC) subgroups separately.

Full Text